Cancer and Risk ofCOVID-19 Through a General Community Survey
Cancer and Risk ofCOVID-19 Through a General Community Survey
复制标题
DOI：
10.1634/theoncologist.2020-0572
复制
发表时间：
2020-09-07
期刊：
影响因子：
5.8
通讯作者：
Chan, Andrew T.
中科院分区：
文献类型：
--
作者：
Lee, Karla A.;Ma, Wenjie;Chan, Andrew T.
癌症患者可能面临2019冠状病毒病（COVID-19）和不良后果的高风险。然而，来自大规模人群研究的证据，检查癌症和癌症相关治疗是否会加剧COVID-19感染的风险，仍然有限。数据收集自2020年3月29日至5月8日的COVID症状研究智能手机应用程序。在23，266名癌症患者和1，784，293名非癌症患者中，我们记录了10，404份COVID-19检测阳性报告。与未患癌症的参与者相比，癌症患者COVID-19检测呈阳性的风险增加了60%。在癌症患者中，目前接受化疗或免疫治疗的患者阳性检测风险增加2.2倍。癌症与COVID-19感染之间的关联在>65岁的参与者和男性中更强。未来的研究需要根据肿瘤类型和治疗方案来确定特别有可能发生COVID-19感染和不良后果的亚组。
Individuals with cancer may be at high risk for coronavirus disease 2019 (COVID-19) and adverse outcomes. However, evidence from large population-based studies examining whether cancer and cancer-related therapy exacerbates the risk of COVID-19 infection is still limited. Data were collected from the COVID Symptom Study smartphone application since March 29 through May 8, 2020. Among 23,266 participants with cancer and 1,784,293 without cancer, we documented 10,404 reports of a positive COVID-19 test. Compared with participants without cancer, those living with cancer had a 60% increased risk of a positive COVID-19 test. Among patients with cancer, current treatment with chemotherapy or immunotherapy was associated with a 2.2-fold increased risk of a positive test. The association between cancer and COVID-19 infection was stronger among participants >65 years and males. Future studies are needed to identify subgroups by tumor types and treatment regimens who are particularly at risk for COVID-19 infection and adverse outcomes.